(Q38117028)

29 August 2017

New obesity agents: lorcaserin and phentermine/topiramate (English)

1 reference

29 August 2017

0 references

Joshua W Fleming

1

1 reference

29 August 2017

Katie S McClendon

series ordinal

2

1 reference

29 August 2017

Daniel M Riche

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

Annals of Pharmacotherapy

29 August 2017

1 reference

29 August 2017

47

1 reference

29 August 2017

7-8

1 reference

29 August 2017

1007-1016

1 reference

Targets for medical therapy in obesity

29 August 2017

1 reference

Annual medical spending attributable to obesity: payer-and service-specific estimates

21 January 2018

1 reference

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

Orlistat: current status in clinical therapeutics

21 January 2018

1 reference

Pharmacologic therapies for obesity

21 January 2018

1 reference

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

21 January 2018

1 reference

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.

21 January 2018

1 reference

The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control

21 January 2018

1 reference

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R779

1 reference

29 August 2017

1 reference